Patients with human immunodeficiency virus (HIV) are an increasing subpopulation of patients seen in endocrine/ diabetes clinics. This article explores evidence-based treatment recommendations for patients with metabolic syndrome who are also positive for HIV. Patients infected with HIV may manifest metabolic abnormalities. They often present with low high-density lipoprotein (HDL-C), hypertension, visceral adiposity, and insulin resistance, among other symptoms consistent with features of the metabolic syndrome. The etiologies of the metabolic abnormalities are not completely understood. The role of highly active antiretroviral therapy (HAART) and the separate effect of HIV on patients who are surviving longer may contribute to the increased incidence of the development of the metabolic syndrome. The role of the health care team is to provide patient education to patients with HIV concerning lifestyle modification in order to prevent complications related to the metabolic syndrome.
Get full access to this article
View all access options for this article.
References
1.
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID).How HIV causes AIDS. Available at: www.3.niaid.nih.gov/HIVAIDS/Understanding/cause. Accessed November 12, 2008.
2.
Fichtenbaum CJ, Hadigan CM, Kotler DP, et al. Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy . IAPAC Monthly. February 2005:38-46.
3.
Gkrania-Klotsas E., Klotsas AEHIV and HIV treatment: effects on fats, glucose and lipids. BMB. 2007;1093:1-20.
4.
Stein JH, Hadigan CM, Brown TT, et al. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation. 2008;118:e54-e60.
5.
National Institutes of Health (NIH).DHHS Panel on Adult and Adolescent Antiretroviral Treatment Guidelines. Available at: http://www.aidsinfo.nih.gov. Accessed April 14, 2009.
6.
Thomson Reuters.Micromedex. Available at: http://www.thomsonhc.com/hcs/librarian . Accessed January 25, 2008.
7.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
8.
Vaidya D., Szklo M., Liu K., Schreiner PJ, Bertoni AG, Ouyang P.Defining the metabolic syndrome construct: multi-ethnic study of atherosclerosis cross-sectional analysis. Diabetes Care. 2007 ;30(5):2086-2090.
Norris A., Dreher HMLipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection. J Assoc of Nurses in AIDS Care. 2004;15(6):46-64.
11.
Jacobson DL , Tang AM, Spiegelman D., et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (national health and nutrition examination survey). J Acquir Immune Defic Syndr. 2006;43(4):458-466.
12.
Mondy K., Overton ET, Grubb J., et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infec Dis. 2007;44:726-734.
13.
Larson R., Capili B., Eckert-Norton M., Colagreco JP, Anastasi JKDisorders of glucose metabolism in the context of human immunodeficiency virus infection. J AANP. 2006;18:92-103.
14.
Smith JC, Evans LM, Wilkinson I., et al. Effects of GH replacement on endothelial function and large artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clinical Endocrinology. 2002;56:493-501.
15.
Vigouroux C. , Maachi M., Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17:1503-1511.
16.
Samarasinghe Y., McIntosh C.Diabetes and HIV: the role of a specialist clinic. Pract Diab Int.2005;22(4):131-137.
17.
Graber ALSyndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection. Endocrine Practice. 2001;7(6): 430-437.
18.
Woerle HJ, Mariuz PR, Meyer C., et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003;52(4):918-925.
19.
Polgreen PM , Putz D., Stapleton JTInaccurate glycosylated hemoglobin A1c measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infec Dis. 2003;37:e53-e56.
20.
Wilson PW, D’Agostina RB, Levy D., Belanger AM, Silbershatz H., Kannel WBPrediction of coronary heart disease using risk factor categories . Circulation. 1998;97:1837-1847.
21.
National Heart, Lung and Blood Institute (NHLBI).Framingham scoring sheet. Available at: http://www.nhlbi.gov . Accessed January 5, 2008.
22.
Muzio F., Mondazzi L., Harris WS, Sommariva D., Branchi A.Effects of moderate variations in the macronutrient content of the diet on cardiovascular disease risk factors in obese patient with the metabolic syndrome . Am J Clin Nutr. 2007;86:946-951.
23.
United States Department of Health and Human Services.NCCAM Research Report: Treating Type 2 Diabetes With Dietary Supplements . Bethesda, Maryland: National Institutes of Health; 2005.
24.
Ciechanowski P., Katon WJThe interpersonal experience of health care through the eyes of patients with diabetes. Soc Sci Med. 2006;63:3067-3079.
25.
Endocrine Society’s Practice Guideline.Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk. J Clin Endocrinol Metab.2008;93:3671-3689.
26.
Agency for Healthcare Research and Quality.Clinician Summary Guide: Comparing Oral Medications for Adults With Type 2 Diabetes. Rockville, Maryland: Agency for Healthcare Research and Quality; 2007.
27.
Robinson FP , Quinn LT, Rimmer JHEffects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study. Bio Res Nurs. 2007;8(3):177-185.
28.
Fitch KV, Anderson EJ, Hubbard JL, et al. Effects of lifestyle modification program in HIV-infected patients with metabolic syndrome. AIDS. 2006;20:1843-1850.
29.
Roza AM, Shizgal HMThe Harris Benedict equation re-evaluated: resting energy requirements and the body cell mass. Am J Clin Nutr. 1984 ;40(1):168-182.
30.
Yarasheski KE, Roubenoff R.Exercise treatment for HIV associated metabolic and anthropomorphic complications. Exercise Sport Sci Rev . 2001;29(4):170-174.
31.
Baca CT, Yahne CESmoking cessation during substance abuse treatment: what you need to know . J Substance Abuse Treatment. 2008 ;36(2):205-219.
32.
Syx RLThe practice of patient education the theoretical perspective. Orthopaedic Nursing. 2008;27(1):50-54.
33.
Kara M., van der Bijl JJ, Shortridge-Baggett LM, Asti T., Erguney S.Cross-cultural adaptation of the diabetes management self-efficacy scale for patients with type 2 diabetes mellitus: scale development. International J Nursing Studies.2005;43(2006): 611-621.
34.
Kibble SE, Harmer C., Brooks A.Taking the lid off Pandora’s box . . . gently. Pract Diab Int. 2007;24(8):398-401.
35.
Funnell MMPatient empowerment. Crit Care Nur Q.2004 ;27(2):201-204.
36.
Phillips KD , Sowell RL, Rush C., Murdaugh C.Psychosocial and physiologic correlates of perceived health among HIV-infected women. Southern Online J Nurs Res. 2001;3(2):1-25.
37.
Waldrop-Valverde D., Valverde E.Homelessness and psychological distress as contributors to antiretroviral non-adherence in HIV-positive injecting drug users. AIDS Patient Care and STDs. 2005 ;19(5):326-334.
38.
Bloomgarden ZTAspects of type 2 diabetes and related insulin-resistant states. Diabetes Care. 2006;29(3):732-740.
39.
Grinspoon S.Physiologic effects of GHRH in patients with HIV lipodystrophy: a model of acquired visceral adiposity. Nature Clin Prac Endoc Met.2006;2(7):355.
40.
Falutz J., Allas S., Blot K., et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. NEJM. 2007;357(23):2359-2369.
41.
Press NM, Montaner JSG, Bondy G.Resolution of diabetes after initiation of antiretroviral therapy in two human immunodeficiency virus-infected patients. Endocrine Practice . 2004;10(3):199-202.
42.
Mascolini M.Rethinking STIs, revamping salvage, revisiting toxicity or the clouds of chronicity. IAPAC Monthly. May 2004:154-176.
